Benjamin Toll, PhD
About
Research
Overview
Dr. Toll’s primary research interest involves developing novel psychosocial and pharmacological treatments for tobacco use disorders. Current studies focus on message framing to promote smoking cessation. He has been working with the New York State Smokers' Quitline on studies testing gain-framed counseling (e.g., if you quit smoking you will live longer) and mediators and moderators of responses to gain-framed counseling. He has also been working on studies of naltrexone for minimization of post smoking cessation weight gain. In addition, Dr. Toll is involved in several studies of psychometrics, assessment, and methodological issues with addictive behaviors.
- “Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers” This project will be a secondary analysis of our New York State Smokers’ Quitline data.
- “Smoking Cessation to Improve Survival Rates of Head and Neck Cancer Patients” This project is an 8-week, open label clinical trial comparing smoking cessation treatment with varenicline 2 mg to nicotine patch 21 mg in a sample of 30 patients who completed treatment for head and neck cancer.
Medical Research Interests
Global Health; Psychiatry; Smoking Cessation
Academic Achievements & Community Involvement
News
News
- February 12, 2025
Fucito Awarded Grant by National Cancer Institute
- May 16, 2024
First U.S. Trial of Varenicline for E-cigarette Cessation Shows Positive Results
- June 30, 2021Source: Preventive Medicine Reports
Use and Perceptions of Electronic Nicotine Delivery Systems Among Patients Attending Lung Cancer Screening Who Smoke
- February 07, 2019
Krishnan-Sarin, Toll elected to SRNT board
Get In Touch
Contacts
Appointment Number